Achillion is focused on solutions for the most challenging problems in infectious disease
Achillion is an innovative biopharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The Company's highly skilled and experienced discovery and development teams have advanced multiple product candidates with proven mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease including HCV.
Achillion is advancing a second-generation NS5A inhibitor, ACH-3102, a potent inhibitor of HCV NS5A that demonstrates pico-molar potency, pan-genotypic activity, and an enhanced resistance profile compared to first-generation NS5A inhibitors. Achillion is also advancing once-daily NS3/4A protease inhibitors including ACH-2684, a potent, second-generation compound entering Phase 2, and sovaprevir, a next-generation protease inhibitor which is currently on clinical hold by the Food and Drug Administration (FDA). Lastly, Achillion has discovered a novel nucleotide NS5B polymerase inhibitor, ACH-3422. Each of these programs was discovered through Achillion's own proprietary internal drug discovery efforts.
Achillion is headquartered in New Haven, Connecticut. Achillion's common stock trades on the NASDAQ Global Select Market under the symbol: ACHN.